GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (TSX:FRX) » Definitions » 5-Year RORE %

Fennec Pharmaceuticals (TSX:FRX) 5-Year RORE % : -0.55% (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Fennec Pharmaceuticals 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Fennec Pharmaceuticals's 5-Year RORE % for the quarter that ended in Dec. 2023 was -0.55%.

The industry rank for Fennec Pharmaceuticals's 5-Year RORE % or its related term are showing as below:

TSX:FRX's 5-Year RORE % is ranked better than
59.15% of 1055 companies
in the Biotechnology industry
Industry Median: -7.26 vs TSX:FRX: -0.55

Fennec Pharmaceuticals 5-Year RORE % Historical Data

The historical data trend for Fennec Pharmaceuticals's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals 5-Year RORE % Chart

Fennec Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.83 20.82 5.72 10.75 -0.55

Fennec Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.75 11.98 9.71 4.51 -0.55

Competitive Comparison of Fennec Pharmaceuticals's 5-Year RORE %

For the Biotechnology subindustry, Fennec Pharmaceuticals's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fennec Pharmaceuticals's 5-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's 5-Year RORE % falls into.



Fennec Pharmaceuticals 5-Year RORE % Calculation

Fennec Pharmaceuticals's 5-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -0.823--0.849 )/( -4.698-0 )
=0.026/-4.698
=-0.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 5-year before.


Fennec Pharmaceuticals  (TSX:FRX) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Fennec Pharmaceuticals 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Fennec Pharmaceuticals (TSX:FRX) Business Description

Traded in Other Exchanges
Address
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Fennec Pharmaceuticals (TSX:FRX) Headlines

From GuruFocus

Beachbody CEO Letter to Forest Road Shareholders

By Business Wire Business Wire 06-09-2021